MedTrace Logo

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 904

Last updated 2026-05-12

No results posted yet for this study

Summary

Researchers are looking for more ways to treat advanced renal cell carcinoma (RCC) that is recurrent. Researchers want to learn if recurrent advanced renal cell carcinoma (RCC) responds (gets smaller or goes away) after treatment with belzutifan (MK-6482) and zanzalintinib compared to cabozantinib.

The goal of this study is to learn if:

People who take belzutifan and zanzalintinib live longer overall and without the cancer getting worse than people who take cabozantinib.

Conditions

Interventions

DRUG

Belzutifan

Administered orally QD

DRUG

Zanzalintinib

Administered orally QD

DRUG

Cabozantinib

Administered orally QD

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-26
Primary Completion
2032-02-27
Completion
2032-02-27
FDA Drug
Yes

Countries

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Croatia
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Hong Kong
  • Ireland
  • Italy
  • Mexico
  • Poland
  • Singapore
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227402 on ClinicalTrials.gov